Clinical Trials - Patient

Clinical Trials - Patient

Use the search below to find a complete list of what is available in our state and who you can contact for more information.

Title Phase Contact(s)
A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study of Ruxolitinib with Front Line Neoadjuvant and Post Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (GY007) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study Testing the Addition of the Antibody Atezolizumab to Chemotherapy with Liposomal Doxorubicin and Bevacizumab in Recurrent Ovarian Cancer (GY009)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination with Nivolumab in Subjects with Non-Small Cell Lung Cancer and Subjects with Metastatic Melanoma (APX005M-002) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination with Nivolumab in Subjects with Non-Small Cell Lung Cancer and Subjects with Metastatic Melanoma (APX005M-002) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Trial Assessing The Tolerability Of Palbociclib In Combination With Letrozole Or Fulvestrant In Patients Aged 70 And Older With Estrogen Receptor Positive, Her2-Negative Metastatic Breast Cancer (A171601) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (A151216) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
An Exploratory Study of Nivolumab with Standard of Care Therapy vs Standard of Care Therapy for First Line Treatment of Metastatic Colorectal Cancer(17186 CA2099X8) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
An Observational Study Assessing the Clinical Effectiveness of the VeriStrat Test and Validating Immunotherapy tests in Subjects with NonSmall Cell Lung Cancer (BDX-00146)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
An Open Label Study to Investigate the Efficacy and Safety of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Patients with Stage IB, II, IIIA, or Selected IIIB Resectable and Untreated NonSmall Cell Lung Cancer (GO40241)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
An Open-Label Study of Itacitinib in Combination with Low Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects with Myelofibrosis (17085) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery (GU002) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Blood Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Melanoma(2018-03)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Cancer Repository for Head and Neck Cancer (253-13)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Clinical Trial Evaluating Post- Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After (B51) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Comparison Study of Thoracic Radiation Regimens in Patients with Limited Stage Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide (RTOG-0538) (C30610) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Conservative Surgery for Women with Low-Risk, Early Stage Cervical Cancer (MDA 2008-0118)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Crizotinib vs Placebo for Patients with Tumors Harboring the ALK Fusion Protein (E4512) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
De-Escalation Protocol of HPV Mediated Oropharyngeal Squamous Cell Carcinaoma Based on the American Joint Committee on Cancer Care 8th Edition Staging Manual (MECC-HN01)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Electronic Patient Reporting Of Symptoms During Cancer Treatment (AFT-39) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Integrated Cancer Repository for Cancer Research (iCaRe2) – Breast Cancer Collaborative Repository - BCCR III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Molecular Analysis for Therapy Choice (NCI MATCH) (EAY131) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Multiple Phase Cohorts of Nivolumab Monotherapy or Nivolumab Combination Regimens Across Relapsed or Refractory Hematologic Malignancies (CA209-039)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Olanzapine with or without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Patients Receiving Highly Emetogenic Chemotherapy (HEC) (A221602) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850

Pages

 
 
Become a NOS Member Today!
 

Platinum Corporate Members

Gold Corporate Members